Fulcrum Therapeutics to Present Initial Data from Phase 1b Trial of FTX-6058 in Adults Living with Sickle Cell Disease at the European Hematology Association (EHA) Hybrid Congress in Vienna, Austria
- FTX-6058 is the only oral hemoglobin F (HbF) inducer in clinical development
-Data will include initial HbF changes, safety, tolerability, pharmacokinetics, and other pharmacodynamic measures from the ongoing 6 mg dose cohort of FTX-6058 in adults with sickle cell disease (SCD)
- Investor webcast to be hosted on June 10th at 8 a.m. EDT
CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it will be presenting two posters at the European Hematology Association (EHA) Hybrid Congress which will take place June 9-12, 2022, in Vienna, Austria. A third abstract has also been accepted for publication. The accepted abstracts are now available online through the EHA website at www.ehaweb.org.
"HbF is the only mechanism that has shown the ability to broadly improve clinical outcomes for patients with SCD— including anemia, vaso-occlusive crises, pain, fatigue, and acute chest syndrome," said Judy Dunn, Ph.D., president of research and development at Fulcrum. “This Phase 1b study was designed to provide proof-of-concept that FTX-6058 produces increases in HbF and could potentially be the first oral HbF inducer to address critical unmet needs in this population."
In addition to the poster presentation, Fulcrum will host a virtual investor event on June 10th at 8 a.m. EDT to review these initial FTX-6058 data and provide a program update.
Poster Presentation Information
Title: Interim results of safety, tolerability, pharmacokinetics, and pharmacodynamics from an ongoing
Title: Inhibition of polycomb repressive complex 2 through EED induces fetal hemoglobin in healthy
Title: A Systematic Literature Review Describing Protective Effects of HbF in Sickle Cell Disease Outcomes
About Fulcrum Therapeutics